10041 Results for "

Metabolic disease

" in MedChemExpress (MCE) Product Catalog:
Products (10041)

10041 Results for "Metabolic disease" in MCE Product Catalog:

105
105 Publications Verification
Cat. No.: HY-P0035A
CAS No.: 11061-68-0
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus .
loading...
    loading...
102
102 Cited Publications
Cat. No.: HY-15304
CAS No.: 304448-55-3
Purity:  99.66%
Research Areas:  

Metabolic Disease

Dynasore is a cell-permeable dynamin inhibitor with an IC50 of 15 μM. Dynasore blocks cell migration.
loading...
    loading...
93
93 Cited Publications
Cat. No.: HY-100596
CAS No.: 836620-48-5
Purity:  99.88%
Target:  

Autophagy

Research Areas:  

Metabolic Disease

AS1842856, a specific Foxo1 inhibitor (IC50=30 nM), potently suppresses autophagy . AS1842856 reduces Foxo1 activity and, to a lesser extent, inhibits Foxo1 protein expression by simply binding to Foxo1 .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-114180
CAS No.: 2262452-06-0
Purity:  99.95%
Synonyms: RU320521
Research Areas:  

Metabolic Disease

RU.521 (RU320521) is a potent and selective cyclic GMP-AMP synthase (cGAS) inhibitor and inhibits cGAS-mediated interferon upregulation. RU.521 suppresses dsDNA-activated reporter activity with an IC50 of 0.7 μM. RU.521 reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome (AGS) .
loading...
    loading...
74
74 Cited Publications
Cat. No.: HY-19707
CAS No.: 14003-96-4
Synonyms: IRE1 Inhibitor III
Target:  

IRE1

Research Areas:  

Metabolic Disease

4μ8C (IRE1 Inhibitor III) is a small-molecule inhibitor of IRE1α.
loading...
    loading...
70
70 Cited Publications
Cat. No.: HY-10585A
CAS No.: 1069-66-5
Purity:  98.14%
Synonyms: Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
loading...
    loading...
70
70 Cited Publications
Cat. No.: HY-10585
CAS No.: 99-66-1
Purity:  99.19%
Synonyms: VPA; 2-Propylpentanoic acid; Dipropylacetic acid
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-101491
CAS No.: 2095432-55-4
Purity:  99.87%
Target:  

PGC-1α Autophagy

Research Areas:  

Metabolic Disease

SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
loading...
    loading...
64
64 Cited Publications
Cat. No.: HY-10532
CAS No.: 925434-55-5
Purity:  99.90%
Target:  

Sirtuin Autophagy

Research Areas:  

Metabolic Disease

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
loading...
    loading...
64
64 Cited Publications
Cat. No.: HY-15145
CAS No.: 2060259-60-9
Purity:  99.37%
Target:  

Sirtuin Autophagy

Research Areas:  

Metabolic Disease

SRT 1720 monohydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .
loading...
    loading...
64
64 Cited Publications
Cat. No.: HY-15145A
CAS No.: 2468639-77-0
Purity:  99.19%
Target:  

Sirtuin Autophagy

Research Areas:  

Metabolic Disease

SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-100111
CAS No.: 835598-94-2
Purity:  99.48%
Target:  

NADPH Oxidase

Research Areas:  

Metabolic Disease

GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
loading...
    loading...
55
55 Cited Publications
Cat. No.: HY-13992
CAS No.: 195514-80-8
Purity:  99.85%
Synonyms: B/B Homodimerizer
Target:  

FKBP

Research Areas:  

Metabolic Disease

AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-17538
CAS No.: 49671-76-3
Target:  

PGC-1α Autophagy

Research Areas:  

Metabolic Disease

ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) .
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-B0445
CAS No.: 53-84-9
Synonyms: β-DPN; β-NAD; β-Nicotinamide Adenine Dinucleotide
NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-B0445A
CAS No.: 20111-18-6
Synonyms: β-DPN sodium; β-NAD sodium; β-Nicotinamide Adenine Dinucleotide sodium
NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance .
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-112053
CAS No.: 1898-66-4
Purity:  98.77%
Synonyms: 2,2-Diphenyl-1-picrylhydrazyl
DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that can be used to measure the radical scavenging activity of antioxidants. The odd electron of nitrogen atom in DPPH is reduced by receiving a hydrogen atom from antioxidants to the corresponding hydrazine. DPPH method may be utilized in aqueous and nonpolar organic solvents and can be used to examine both hydrophilic and lipophilic antioxidants .
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-119738
CAS No.: 1681056-61-0
Purity:  99.90%
Target:  

OGT Acyltransferase

Research Areas:  

Metabolic Disease

OSMI-1 is a cell-permeable O-GlcNAc transferase (OGT) inhibitor with an IC50 value of 2.7 μM. OSMI-1 inhibits protein O-linked N-acetylglucosamine (O-GlcNAcylation) in several mammalian cell lines without qualitatively altering cell surface N- or O-linked glycans .
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-114118
CAS No.: 910463-68-2
Purity:  99.84%
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-114118B
CAS No.: 1997361-85-9
Purity:  99.92%
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...